Neurocrine Biosciences Q2 2026 revenue jumps 39% to $959 million

Stronger INGREZZA sales and non-GAAP earnings of $2.85 per share helped the company beat estimates and lift its 2026 sales outlook.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.